CRT Appoints Board Member
This article was originally published in Scrip
Cancer Research Technology (CRT) has appointed Dr. Deborah Harland to its board as non-executive director. Deborah, who has held various roles in business development, clinical development and medical affairs, is currently a partner at the corporate venture capital arm of GlaxoSmithKline, SR One. She is also on the board of various biotech companies, in which SR One has invested, including Mission Therapeutics.